Disrupting HER2-ER crosstalk may be effective only in a subset of patients, and activation of alternative tumor survival pathways—such as the cyclin D1–CDK4/6 axis—may limit efficacy [15]. This evidence concerns the gene ERBB2 and neoplasm.